RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor
Two novel biomarkers of Alzheimer's disease in human plasma
Cutler, P., Akuffo, E. L., Bodnar, W. M., Briggs, D. M., Davis, J. B., Debouck, C. M., Fox, S. M., Gibson, R. A., Gormley, D. A., Holbrook, J. D., Hunter, A. J., Kinsey, E. E., Prinjha, R., Richardson, J. C., Roses, A. D., Smith, M. A., Tsokanas, N., Willé, D. R., Wu, W., ... Gloger, I. S. (2008). Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics. Clinical Applications, 2(4), 467-477. https://doi.org/10.1002/prca.200780101
Emerging disease modifying therapeutic strategies for Alzheimer's disease (AD) have generated a critical need for biomarkers of early stage disease. Here, we describe the identification and assessment of a number of candidate biomarkers in patients with mild to moderate probable AD. Plasma from 47 probable Alzheimer's patients and 47 matched controls were analysed by proteomics to define a significant number of proteins whose expression appeared to be associated with AD. These were compared to a similar proteomic comparison of a mouse transgenic model of amyloidosis, which showed encouraging overlap with the human data. From these studies a prioritised list of 31 proteins were then analysed by immunoassay and/or functional assay in the same human cohort to verify the changes observed. Eight proteins continued to show significance by either immunoassay or functional assay in the human plasma and these were tested in a further set of 100 probable AD patients and 100 controls from the original cohort. From our data it appeared that two proteins, serpin F1 (pigment epithelium-derived factor) and complement C1 inhibitor are down-regulated in plasma from AD patients.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.